Advances in -omics technology allow delineation of pathways, which will be particularly important in TH2 low eosinophilic asthma, and also pauci-inflammatory disease.
Advances in -omics technology allow delineation of pathways, which will be particularly important in TH2 low eosinophilic asthma, and also pauci-inflammatory disease.Tags: Javanet Business PlanWork Training CoursesFront Page Design For AssignmentSteps To Solve A Word ProblemWorking At Home EssayResearch Paper On Conflict ManagementUva Supplement EssayEssay On A Rose For Emily Symbolism
However, a critical review of the evidence shows that this view is untenable.
Three monoclonal antibody therapies (benralizumab, mepolizumab and omalizumab) are available in Australia for the treatment of patients with severe asthma whose asthma is uncontrolled despite optimised standard treatment.
This information paper is a new evidence-based resource for primary care health professionals to help explain the latest treatment options for patients with severe asthma. Apart from providing a financial grant, GSK Australia has not been involved in the development, recommendation, review or editing of this publication. Although all care has been taken, this information paper is a general guide only, which is not a substitute for assessment of appropriate courses of treatment on a case-by-case basis.
Please set your browser to accept cookies to continue.